Trump faces drugmakers that treat sick Americans like ATMs
Deagreez via iStock/Getty Images
Meanwhile, prices keep climbing. Since Trump left office after his first term, cancer drug prices rose faster than Biden-era inflation. Median list prices for new medicines more than doubled between 2021 and 2024, surpassing $300,000 a year. In 2023 alone, drug companies raised prices by 35%. The Rand Corporation found that Americans spent more than $600 billion on prescriptions in 2022 — almost triple what patients in other developed nations pay.
Competition, not cronyism
Families facing cancer now shoulder thousands more out of pocket while Big Pharma posts record profits. Trump deserves credit for recognizing how unfair practices and Democrat policies pushed drug costs beyond the reach of average households.
A better path is within reach. Real reform depends on competition rather than political connections. Trump can break the illusion by opening the market, lowering barriers to entry, and cutting regulatory burdens that keep smaller firms out. He should expose the game Big Pharma has played for years and force the industry to compete in a real marketplace.
Leave a Reply
You must be logged in to post a comment.